Literature DB >> 25229211

Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study.

Sylvia Rabstein1, Volker Harth, Christina Justenhoven, Beate Pesch, Sabine Plöttner, Evelyn Heinze, Anne Lotz, Christian Baisch, Markus Schiffermann, Hiltrud Brauch, Ute Hamann, Yon Ko, Thomas Brüning.   

Abstract

OBJECTIVES: The role of genetic variants and environmental factors in breast cancer etiology has been intensively studied in the last decades. Gene-environment interactions are now increasingly being investigated to gain more insights into the development of breast cancer, specific subtypes, and therapeutics. Recently, night shift work that involves circadian disruption has gained rising interest as a potential non-genetic breast cancer risk factor. Here, we analyzed genetic polymorphisms in genes of cellular clocks, melatonin biosynthesis and signaling and their association with breast cancer as well as gene-gene and gene-night work interactions in a German case-control study on breast cancer.
METHODS: GENICA is a population-based case-control study on breast cancer conducted in the Greater Region of Bonn. Associations between seven polymorphisms in circadian genes (CLOCK, NPAS2, ARTNL, PER2 and CRY2), genes of melatonin biosynthesis and signaling (AANAT and MTNR1B) and breast cancer were analyzed with conditional logistic regression models, adjusted for potential confounders for 1022 cases and 1014 controls. Detailed shift-work information was documented for 857 breast cancer cases and 892 controls. Gene-gene and gene-shiftwork interactions were analyzed using model-based multifactor dimensionality reduction (mbMDR).
RESULTS: For combined heterozygotes and rare homozygotes a slightly elevated breast cancer risk was found for rs8150 in gene AANAT (OR 1.17; 95% CI 1.01-1.36), and a reduced risk for rs3816358 in gene ARNTL (OR 0.82; 95% CI 0.69-0.97) in the complete study population. In the subgroup of shift workers, rare homozygotes for rs10462028 in the CLOCK gene had an elevated risk of breast cancer (OR for AA vs. GG: 3.53; 95% CI 1.09-11.42). Shift work and CLOCK gene interactions were observed in the two-way interaction analysis. In addition, gene-shiftwork interactions were detected for MTNR1B with NPAS2 and ARNTL.
CONCLUSIONS: In conclusion, the results of our population-based case-control study support a putative role of the CLOCK gene in the development of breast cancer in shift workers. In addition, higher order interaction analyses suggest a potential relevance of MTNR1B with the key transcriptional factor NPAS2 with ARNTL. Hence, in the context of circadian disruption, multivariable models should be preferred that consider a wide range of polymorphisms, e.g. that may influence chronotype or light sensitivity. The investigation of these interactions in larger studies is needed.

Entities:  

Keywords:  Case-control study; genetic variants; shift work

Mesh:

Substances:

Year:  2014        PMID: 25229211     DOI: 10.3109/07420528.2014.957301

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  13 in total

1.  Sleep and immunity: A growing field with clinical impact.

Authors:  Mark R Opp; James M Krueger
Journal:  Brain Behav Immun       Date:  2015-04-04       Impact factor: 7.217

Review 2.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

3.  Melatonin-induced KiSS1 expression inhibits triple-negative breast cancer cell invasiveness.

Authors:  Tae-Hun Kim; Sung-Gook Cho
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

4.  Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma.

Authors:  Chao-Yuan Huang; Shu-Pin Huang; Yu-Mei Hsueh; Lih-Chyang Chen; Te-Ling Lu; Bo-Ying Bao
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

5.  Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.

Authors:  Fangyi Gu; Han Zhang; Paula L Hyland; Sonja Berndt; Susan M Gapstur; William Wheeler; The Ellipse Consortium; Christopher I Amos; Stephane Bezieau; Heike Bickeböller; Hermann Brenner; Paul Brennan; Jenny Chang-Claude; David V Conti; Jennifer Anne Doherty; Stephen B Gruber; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; Richard S Houlston; Rayjean J Hung; Mark A Jenkins; Peter Kraft; Kate Lawrenson; James McKay; Sarah Markt; Lorelei Mucci; Catherine M Phelan; Conghui Qu; Angela Risch; Mary Anne Rossing; H-Erich Wichmann; Jianxin Shi; Eva Schernhammer; Kai Yu; Maria Teresa Landi; Neil E Caporaso
Journal:  Int J Cancer       Date:  2017-07-29       Impact factor: 7.316

Review 6.  CAG repeat polymorphisms in the androgen receptor and breast cancer risk in women: a meta-analysis of 17 studies.

Authors:  Qixing Mao; Mantang Qiu; Gaochao Dong; Wenjie Xia; Shuai Zhang; Youtao Xu; Jie Wang; Yin Rong; Lin Xu; Feng Jiang
Journal:  Onco Targets Ther       Date:  2015-08-13       Impact factor: 4.147

Review 7.  Prevention of fatigue and insomnia in shift workers-a review of non-pharmacological measures.

Authors:  Kneginja Richter; Jens Acker; Sophia Adam; Guenter Niklewski
Journal:  EPMA J       Date:  2016-08-02       Impact factor: 6.543

8.  Can yesterday's smoking research inform today's shiftwork research? Epistemological consequences for exposures and doses due to circadian disruption at and off work.

Authors:  Thomas C Erren; Philip Lewis
Journal:  J Occup Med Toxicol       Date:  2017-09-11       Impact factor: 2.646

Review 9.  Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis.

Authors:  Clara Benna; Charlotte Helfrich-Förster; Senthilkumar Rajendran; Halenya Monticelli; Pierluigi Pilati; Donato Nitti; Simone Mocellin
Journal:  Oncotarget       Date:  2017-04-04

Review 10.  Melatonin: A Molecule for Reducing Breast Cancer Risk.

Authors:  Alicia González-González; María Dolores Mediavilla; Emilio J Sánchez-Barceló
Journal:  Molecules       Date:  2018-02-06       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.